Literature DB >> 19155309

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Kenneth H Shain1, Danielle N Yarde, Mark B Meads, Mei Huang, Richard Jove, Lori A Hazlehurst, William S Dalton.   

Abstract

The bone marrow microenvironmental components interleukin (IL)-6 and fibronectin (FN) individually influence the proliferation and survival of multiple myeloma (MM) cells; however, in vivo, these effectors most likely work together. We examined signaling events, cell cycle progression, and levels of drug response in MM cells either adhered to FN via beta1 integrins, stimulated with IL-6, or treated with the two combined. Although G(1)-S cell cycle arrest associated with FN adhesion was overcome when IL-6 was added, the cell adhesion-mediated drug resistance (CAM-DR) was maintained in the presence of IL-6. Concomitant exposure of MM cells to IL-6 and FN adhesion revealed a dramatic increase in signal transducers and activators of transcription 3 (STAT3) phosphorylation, nuclear translocation, and DNA binding, compared with either IL-6 or FN adhesion alone in four MM cell lines. Importantly, this increase in STAT3 activation correlated with a novel association between STAT3 and gp130 in cells adhered to FN before stimulation with IL-6, relative to nonadherent cells. Taken together, these results suggest a mechanism by which collaborative signaling by beta1 integrin and gp130 confers an increased survival advantage to MM cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155309      PMCID: PMC2680075          DOI: 10.1158/0008-5472.CAN-08-2419

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Authors:  J S Damiano; A E Cress; L A Hazlehurst; A A Shtil; W S Dalton
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

2.  Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

Authors:  Lori A Hazlehurst; Raul F Argilagos; Michael Emmons; David Boulware; Craig A Beam; Dan M Sullivan; William S Dalton
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

3.  Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

Authors:  D Chauhan; S Kharbanda; A Ogata; M Urashima; G Teoh; M Robertson; D W Kufe; K C Anderson
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

4.  RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth.

Authors:  Weizhou Zhang; Cong S Zong; Ulrich Hermanto; Pablo Lopez-Bergami; Ze'ev Ronai; Lu-Hai Wang
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Authors:  R Catlett-Falcone; T H Landowski; M M Oshiro; J Turkson; A Levitzki; R Savino; G Ciliberto; L Moscinski; J L Fernández-Luna; G Nuñez; W S Dalton; R Jove
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

6.  Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival.

Authors:  L Moro; M Venturino; C Bozzo; L Silengo; F Altruda; L Beguinot; G Tarone; P Defilippi
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

7.  Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.

Authors:  Katja Brocke-Heidrich; Antje K Kretzschmar; Gabriele Pfeifer; Christian Henze; Dennis Löffler; Dirk Koczan; Hans-Jürgen Thiesen; Renate Burger; Martin Gramatzki; Friedemann Horn
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

8.  Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase.

Authors:  Iris Behrmann; Tanja Smyczek; Peter C Heinrich; Hildegard Schmitz-Van de Leur; Waraporn Komyod; Bernd Giese; Gerhard Müller-Newen; Serge Haan; Claude Haan
Journal:  J Biol Chem       Date:  2004-05-03       Impact factor: 5.157

9.  Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors.

Authors:  S Miyamoto; H Teramoto; J S Gutkind; K M Yamada
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

10.  {beta}1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation.

Authors:  Paola Defilippi; Arturo Rosso; Patrizia Dentelli; Cristina Calvi; Giovanni Garbarino; Guido Tarone; Luigi Pegoraro; Maria Felice Brizzi
Journal:  J Cell Biol       Date:  2005-03-28       Impact factor: 10.539

View more
  82 in total

1.  βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.

Authors:  Deepak Kanojia; Ramin A Morshed; Lingjiao Zhang; Jason M Miska; Jian Qiao; Julius W Kim; Peter Pytel; Irina V Balyasnikova; Maciej S Lesniak; Atique U Ahmed
Journal:  Mol Cancer Ther       Date:  2015-02-27       Impact factor: 6.261

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

3.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

Review 4.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

5.  Integrin β1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma.

Authors:  Zhipeng Xu; Li Zou; Gang Ma; Xiaowei Wu; Furong Huang; Tingting Feng; Suqing Li; Qingfeng Lin; Xiaoting He; Zhihua Liu; Xiufeng Cao
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 6.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

7.  Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.

Authors:  Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

Review 8.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

9.  Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors:  Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

10.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.